PE20181051A1 - Anticuerpo anti-epha4 - Google Patents
Anticuerpo anti-epha4Info
- Publication number
- PE20181051A1 PE20181051A1 PE2017002724A PE2017002724A PE20181051A1 PE 20181051 A1 PE20181051 A1 PE 20181051A1 PE 2017002724 A PE2017002724 A PE 2017002724A PE 2017002724 A PE2017002724 A PE 2017002724A PE 20181051 A1 PE20181051 A1 PE 20181051A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- epha4
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 102000021727 EphA4 Receptor Human genes 0.000 abstract 4
- 108010055179 EphA4 Receptor Proteins 0.000 abstract 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un anticuerpo anti-EphA4 o un fragmento de union a EphA4 del mismo, que comprende: a) CDR-H1 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 26 o la SEQ ID NO: 27; b) CDR-H2 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 28 o la SEQ ID NO: 29; c) CDR-H3 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 30; d) CDR-L1 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 31; e) CDR-L2 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 32; y f) CDR-L3 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 33. En donde dicho anticuerpo es capaz de unirse a EphA4 del mismo e inhibir la union entre EphA4 y su ligando. Tambien se refiere la identificacion de las secuencias de regiones determinantes de complementariedad (CDRs) del anticuerpo anti-EphA4 de raton, y a la preparacion de un anticuerpo humanizado que comprende las secuencias de CDR del anticuerpo antiEphA4 de raton en la region variable de la cadena pesada y la region variable de la cadena ligera. Se utiliza para el tratamiento de la esclerosis lateral amiotrofica (ELA).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015177081 | 2015-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181051A1 true PE20181051A1 (es) | 2018-07-03 |
Family
ID=58240770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002724A PE20181051A1 (es) | 2015-09-08 | 2016-09-06 | Anticuerpo anti-epha4 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10428140B2 (es) |
| EP (1) | EP3381941B1 (es) |
| JP (2) | JP6738814B2 (es) |
| KR (1) | KR20180041136A (es) |
| CN (2) | CN107922499B (es) |
| AR (1) | AR105938A1 (es) |
| AU (1) | AU2016319433A1 (es) |
| BR (1) | BR112018003494A2 (es) |
| CA (1) | CA2989993A1 (es) |
| CO (1) | CO2018000652A2 (es) |
| ES (1) | ES2846175T3 (es) |
| IL (2) | IL256519A (es) |
| MX (2) | MX377865B (es) |
| PE (1) | PE20181051A1 (es) |
| PH (1) | PH12018500290A1 (es) |
| RU (2) | RU2719158C2 (es) |
| SG (1) | SG11201800127WA (es) |
| TW (1) | TW201716442A (es) |
| WO (1) | WO2017043466A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12290516B2 (en) | 2017-05-12 | 2025-05-06 | The Hong Kong University Of Science And Technology | Heterocyclic compounds as EphA4 inhibitors |
| AR112357A1 (es) * | 2017-08-10 | 2019-10-23 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
| JPWO2020184350A1 (es) * | 2019-03-08 | 2020-09-17 | ||
| PH12021553090A1 (en) | 2019-07-01 | 2022-07-25 | Eisai R&D Man Co Ltd | ANTI-EphA4 ANTIBODY |
| CA3192342A1 (en) * | 2020-12-24 | 2022-06-30 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| CN116710133A (zh) | 2020-12-24 | 2023-09-05 | 卫材R&D管理有限公司 | 肌萎缩侧索硬化的治疗用药物组合物 |
| WO2023085320A1 (ja) * | 2021-11-11 | 2023-05-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ＥｐｈＡ４抗体 |
| TW202330615A (zh) * | 2021-11-22 | 2023-08-01 | 中國醫藥大學 | Ｅｐｈｒｉｎ ａ型受體１０特異性抗體、表現其之嵌合抗原受體ｔ細胞及其應用 |
| WO2023122647A2 (en) * | 2021-12-22 | 2023-06-29 | The University Of Chicago | Methods for detecting or treating influenza infections |
| WO2024047558A2 (en) * | 2022-08-31 | 2024-03-07 | Immuneel Therapeutics Private Limited | Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4334271B2 (ja) * | 2003-05-07 | 2009-09-30 | セレスター・レキシコ・サイエンシズ株式会社 | 抗体配列作成装置、抗体配列作成方法、プログラム、および、記録媒体 |
| EP1638514A4 (en) * | 2003-06-06 | 2009-11-18 | Medimmune Inc | USE OF EPHA4 AND MODULATOR OR EPHA4 FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER |
| ATE501173T1 (de) * | 2003-12-04 | 2011-03-15 | Abbott Biotherapeutics Corp | Anti-ip-10-antikörper |
| US20080063640A1 (en) * | 2004-02-27 | 2008-03-13 | Oncotherapy Science, Inc. | Pin-Prc Transition Genes |
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| EP1662259A1 (en) | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| RU2429246C2 (ru) * | 2006-02-28 | 2011-09-20 | Онкотерапи Сайенс, Инк. | СПОСОБЫ РАЗРУШЕНИЯ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ ЭФФЕКТОРНЫХ ФУНКЦИЙ АНТИ-EphA4 АНТИТЕЛ |
| JP5511377B2 (ja) | 2007-06-08 | 2014-06-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | γ−セクレターゼの新規基質ＥｐｈＡ４を利用したスクリーニング方法 |
| WO2009069808A1 (ja) | 2007-11-30 | 2009-06-04 | Eisai R & D Management Co., Ltd. | 新規活性を有するEphA4ポリペプチドおよびその用途 |
| WO2010141974A1 (en) | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| JP2010285413A (ja) * | 2009-06-10 | 2010-12-24 | Univ Of Melbourne | 治療用途 |
| KR20120089863A (ko) * | 2009-10-09 | 2012-08-14 | 사노피 | “개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법 |
| JP6059017B2 (ja) | 2010-12-17 | 2017-01-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法 |
| JP5961608B2 (ja) * | 2011-04-25 | 2016-08-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| US10934360B2 (en) | 2014-07-31 | 2021-03-02 | The Hong Kong University Of Science And Technology | Human monoclonal antibodies against EPHA4 and their use |
-
2016
- 2016-09-06 ES ES16844327T patent/ES2846175T3/es active Active
- 2016-09-06 CN CN201680048438.4A patent/CN107922499B/zh not_active Expired - Fee Related
- 2016-09-06 CA CA2989993A patent/CA2989993A1/en not_active Abandoned
- 2016-09-06 EP EP16844327.3A patent/EP3381941B1/en active Active
- 2016-09-06 CN CN202010179415.5A patent/CN111320693B/zh not_active Expired - Fee Related
- 2016-09-06 RU RU2018106456A patent/RU2719158C2/ru active
- 2016-09-06 BR BR112018003494-0A patent/BR112018003494A2/pt not_active Application Discontinuation
- 2016-09-06 JP JP2017539163A patent/JP6738814B2/ja active Active
- 2016-09-06 AU AU2016319433A patent/AU2016319433A1/en not_active Abandoned
- 2016-09-06 AR ARP160102725A patent/AR105938A1/es unknown
- 2016-09-06 MX MX2018002164A patent/MX377865B/es unknown
- 2016-09-06 KR KR1020187004754A patent/KR20180041136A/ko not_active Withdrawn
- 2016-09-06 RU RU2019128192A patent/RU2019128192A/ru unknown
- 2016-09-06 SG SG11201800127WA patent/SG11201800127WA/en unknown
- 2016-09-06 TW TW105128767A patent/TW201716442A/zh unknown
- 2016-09-06 PE PE2017002724A patent/PE20181051A1/es not_active Application Discontinuation
- 2016-09-06 WO PCT/JP2016/076102 patent/WO2017043466A1/ja not_active Ceased
- 2016-09-06 US US15/753,611 patent/US10428140B2/en active Active
-
2017
- 2017-12-24 IL IL256519A patent/IL256519A/en unknown
-
2018
- 2018-01-24 CO CONC2018/0000652A patent/CO2018000652A2/es unknown
- 2018-02-08 PH PH12018500290A patent/PH12018500290A1/en unknown
- 2018-02-20 MX MX2020002406A patent/MX2020002406A/es unknown
-
2019
- 2019-08-23 JP JP2019152823A patent/JP6770153B2/ja not_active Expired - Fee Related
- 2019-08-25 IL IL26888919A patent/IL268889A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| CL2020003046A1 (es) | Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018) | |
| CY1123212T1 (el) | Συνθεσεις για την αναστολη της ενεργοποιησης του masp-2 εξαρτωμενου συμπληρωματος | |
| CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| JP2016527225A5 (es) | ||
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo | |
| CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| PE20120497A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
| PE20191076A1 (es) | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo | |
| CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| UA108466C2 (en) | Antibody antagonises c-Met | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| NZ599779A (en) | Compositions and methods for treating inflammatory disorders | |
| AR115192A1 (es) | Anticuerpos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |